FDA Approved: ZERBAXA — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for ZERBAXA (ceftolozane/tazobactam) submitted by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hospital-acquired Pneumonia
• Intra-abdominal Infection
• Urinary Tract Infection
• Ventilator-associated Pneumonia

Drugs mentioned

• Zerbaxa (ceftolozane-tazobactam)

Snippet

SUPPL AP for ZERBAXA (CEFTOLOZANE AND TAZOBACTAM)